Meeting of the Lead Exposure and Prevention Advisory Committee, 85216 [2024-24925]

Download as PDF 85216 Federal Register / Vol. 89, No. 207 / Friday, October 25, 2024 / Notices CDC requests OMB approval for an estimated 1,564 annual burden hours. There is no cost to respondents other than their time to participate. ESTIMATED ANNUALIZED BURDEN HOURS Number responses per respondent Avg. burden per response (in hrs.) Total burden (in hrs.) Type of respondent Triazole-resistant Aspergillus fumigatus Case Report Form Coccidioidomycosis Case Report Form ................................ Antifungal-resistant dermatophytosis case report form ........ Chromoblastomycosis case report form ............................... Mycetoma case report form .................................................. Sporotrichosis case report form ............................................ State and Local Health Departments .... State and Local Health Departments .... Private Sectors ...................................... State and Local Health Departments .... Private Sectors ...................................... State and Local Health Departments .... Private Sectors ...................................... State and Local Health Departments .... Private Sectors ...................................... State and Local Health Departments .... Private Sectors ...................................... Private Sectors ...................................... Private Sectors ...................................... 15 10 3 10 3 10 3 15 3 10 25 25 25 15 25 10 25 10 25 10 20 10 10 10 5 10 0.5 1.0 1.0 1.0 1.0 1.0 1.0 0.75 0.75 0.5 0.5 0.5 0.5 113 250 30 250 30 250 30 225 23 50 125 63 125 Total ............................................................................... ............................................................... ...................... .......................... .................... 1,564 Histoplasmosis Case Report Form ....................................... Blastomycosis Case Report Form ........................................ Candida auris Case Report Form ......................................... Jeffrey M. Zirger, Lead, Information Collection Review Office, Office of Public Health Ethics and Regulations, Office of Science, Centers for Disease Control and Prevention. [FR Doc. 2024–24922 Filed 10–24–24; 8:45 am] BILLING CODE 4163–18–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention Meeting of the Lead Exposure and Prevention Advisory Committee Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS). ACTION: Notice of meeting. AGENCY: In accordance with the Federal Advisory Committee Act, the Centers for Disease Control and Prevention announces the following meeting for the Lead Exposure and Prevention Advisory Committee (LEPAC). This virtual meeting is open to the public. Advance registration by December 4, 2024, is needed to receive the information to join the meeting. The registration link is provided in the addresses section below. DATES: The meeting will be held on December 11, 2024 from 11 a.m. to 5 p.m., EST. ADDRESSES: Register in advance https:// events.gcc.teams.microsoft.com/event/ 0e538aa3-bc82-43e9-89ee-d997b498c fe6@9ce70869-60db-44fd-abe8-d27670 77fc8f to receive information to join the meeting. FOR FURTHER INFORMATION CONTACT: Paul Allwood, Ph.D., M.P.H., Designated Federal Officer, National Center for SUMMARY: ddrumheller on DSK120RN23PROD with NOTICES1 Number of respondents Form name VerDate Sep<11>2014 17:40 Oct 24, 2024 Jkt 265001 Environmental Health, Centers for Disease Control and Prevention, 4770 Buford Highway, Atlanta, Georgia 30341, Telephone: 770–488–6774; Email: LEPAC@cdc.gov. SUPPLEMENTARY INFORMATION: Background: The Lead Exposure and Prevention Advisory Committee was established under Section 2203 of Public Law 114–322, the Water Infrastructure Improvements for the Nation Act; 42 U.S.C. 300j–21, Registry for Lead Exposure and Prevention Advisory Committee. Purpose: The LEPAC is charged with providing advice and guidance to the Secretary, Department of Health and Human Services (HHS), and the Director, CDC and Administrator, ATSDR, on (1) reviewing Federal programs and services available to individual communities exposed to lead; (2) reviewing current research on lead exposure to identify additional research needs; (3) reviewing and identifying best practices, or the need for best practices regarding lead screening and the prevention of lead poisoning; (4) identifying effective services, including services relating to healthcare, education, and nutrition for individuals and communities affected by lead exposure and lead poisoning, including in consultation with, as appropriate, the lead exposure registry as established in Section 2203(b) of Public Law 114–322; and (5) undertaking any other review or activities that the Secretary determines to be appropriate. Matters to be Considered: The agenda will include presentations and discussions on the following topics: vote on the 2023 annual LEPAC report, report from the Preventing Lead Exposure in Adults workgroup, lead PO 00000 Frm 00081 Fmt 4703 Sfmt 9990 related updates from the LEPAC members, local perspective on improving blood lead testing, blood lead testing strategies. Agenda items are subject to change as priorities dictate. Public Participation Oral Public Comment: The public comment period is scheduled on December 11, 2024, from 12:30 p.m. until 12:50 p.m., EST. Individuals wishing to make a comment during the public comment period, please email your name, organization, and phone number by November 25, 2024, to LEPAC@cdc.gov. The Director, Office of Strategic Business Initiatives, Office of the Chief Operating Officer, Centers for Disease Control and Prevention, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry. Kalwant Smagh, Director, Office of Strategic Business Initiatives, Office of the Chief Operating Officer, Centers for Disease Control and Prevention. [FR Doc. 2024–24925 Filed 10–24–24; 8:45 am] BILLING CODE 4163–18–P E:\FR\FM\25OCN1.SGM 25OCN1

Agencies

[Federal Register Volume 89, Number 207 (Friday, October 25, 2024)]
[Notices]
[Page 85216]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-24925]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention


Meeting of the Lead Exposure and Prevention Advisory Committee

AGENCY: Centers for Disease Control and Prevention (CDC), Department of 
Health and Human Services (HHS).

ACTION: Notice of meeting.

-----------------------------------------------------------------------

SUMMARY: In accordance with the Federal Advisory Committee Act, the 
Centers for Disease Control and Prevention announces the following 
meeting for the Lead Exposure and Prevention Advisory Committee 
(LEPAC). This virtual meeting is open to the public. Advance 
registration by December 4, 2024, is needed to receive the information 
to join the meeting. The registration link is provided in the addresses 
section below.

DATES: The meeting will be held on December 11, 2024 from 11 a.m. to 5 
p.m., EST.

ADDRESSES: Register in advance https://events.gcc.teams.microsoft.com/event/0e538aa3-bc82-43e9-89ee-d997b498cfe6@9ce70869-60db-44fd-abe8-d2767077fc8f to receive information to join the meeting.

FOR FURTHER INFORMATION CONTACT: Paul Allwood, Ph.D., M.P.H., 
Designated Federal Officer, National Center for Environmental Health, 
Centers for Disease Control and Prevention, 4770 Buford Highway, 
Atlanta, Georgia 30341, Telephone: 770-488-6774; Email: [email protected].

SUPPLEMENTARY INFORMATION: 
    Background: The Lead Exposure and Prevention Advisory Committee was 
established under Section 2203 of Public Law 114-322, the Water 
Infrastructure Improvements for the Nation Act; 42 U.S.C. 300j-21, 
Registry for Lead Exposure and Prevention Advisory Committee.
    Purpose: The LEPAC is charged with providing advice and guidance to 
the Secretary, Department of Health and Human Services (HHS), and the 
Director, CDC and Administrator, ATSDR, on (1) reviewing Federal 
programs and services available to individual communities exposed to 
lead; (2) reviewing current research on lead exposure to identify 
additional research needs; (3) reviewing and identifying best 
practices, or the need for best practices regarding lead screening and 
the prevention of lead poisoning; (4) identifying effective services, 
including services relating to healthcare, education, and nutrition for 
individuals and communities affected by lead exposure and lead 
poisoning, including in consultation with, as appropriate, the lead 
exposure registry as established in Section 2203(b) of Public Law 114-
322; and (5) undertaking any other review or activities that the 
Secretary determines to be appropriate.
    Matters to be Considered: The agenda will include presentations and 
discussions on the following topics: vote on the 2023 annual LEPAC 
report, report from the Preventing Lead Exposure in Adults workgroup, 
lead related updates from the LEPAC members, local perspective on 
improving blood lead testing, blood lead testing strategies. Agenda 
items are subject to change as priorities dictate.

Public Participation

    Oral Public Comment: The public comment period is scheduled on 
December 11, 2024, from 12:30 p.m. until 12:50 p.m., EST. Individuals 
wishing to make a comment during the public comment period, please 
email your name, organization, and phone number by November 25, 2024, 
to [email protected].
    The Director, Office of Strategic Business Initiatives, Office of 
the Chief Operating Officer, Centers for Disease Control and 
Prevention, has been delegated the authority to sign Federal Register 
notices pertaining to announcements of meetings and other committee 
management activities, for both the Centers for Disease Control and 
Prevention and the Agency for Toxic Substances and Disease Registry.

Kalwant Smagh,
Director, Office of Strategic Business Initiatives, Office of the Chief 
Operating Officer, Centers for Disease Control and Prevention.
[FR Doc. 2024-24925 Filed 10-24-24; 8:45 am]
BILLING CODE 4163-18-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.